MedTrace Logo

A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors

NCT05821777 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-09-25

No results posted yet for this study

Summary

The purpose of this study is to assess safety, tolerability, and preliminary activity of LB101 monotherapy in participants with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

LB101

Part 1: IV infusion of LB101 Q2W (28-day cycle) and Part 2: IV infusion of LB101

Sponsors & Collaborators

  • LockBody Therapeutics Ltd

    collaborator INDUSTRY

  • Centessa Pharmaceuticals (UK) Limited

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-28
Primary Completion
2025-01-24
Completion
2025-09-09
FDA Drug
Yes

Countries

  • United States
  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05821777 on ClinicalTrials.gov